grace targeted therapies lung cancer 2021 - recommended treatment for an alk variant 1 patient
Published 2 years ago • 27 plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
21:58
grace targeted therapies lung cancer 2021 - alk therapies-which one comes first, how do we sequence?
-
1:58
grace targeted therapies lung cancer 2021 - other data for alk positive lung cancer?
-
4:31
grace targeted therapies lung cancer 2021 -recommended 2nd line & timing, stage 3 ros-1 lung cancer?
-
2:34
grace targeted therapies lung cancer 2021 - recommended firstline treatment for kras k12c?
-
2:07
grace targeted therapies lung cancer 2021 - ros1 & alk treatments transform neuroendocrine tumor
-
3:06
grace targeted therapies lung cancer 2021 - tki plus chemotherapy as a firstline treatment in ros1?
-
4:06
grace targeted therapies lung cancer 2021 options after progression on alectinib?
-
3:09
grace targeted therapies lung cancer 2021 - best treatment patient with a designated kras mutation
-
2:39
grace targeted therapies lung cancer 2021 - return to alectinib -progression on lorlatinib in alk
-
17:53
grace targeted therapies lung cancer 2021 - genotype directed therapy: role in earlier stage disease
-
11:49
grace targeted therapies lung cancer 2021 - online communities, education & partnership in research
-
2:08
grace targeted therapies lung cancer 2021 - approved therapy for a cdkn2a secondary mutation?
-
16:03
grace targeted therapies lung cancer 2021 -the role of chemotherapy in driver positive patients
-
2:01
grace targeted therapies lung cancer 2021 - data learned from ensartinib for ros1 in clinical trial?
-
4:42
grace targeted therapies in lung cancer 2021 - anxiety burden: wait for results, beginning treatment
-
1:39
grace targeted therapies lung cancer 2021 - treatment after crizotinib in ros1 lung cancer
-
14:33
grace targeted therapies lung cancer 2021 - targeted therapies in oligo-metastatic disease
-
17:58
grace targeted therapies lung cancer 2021 - kras directed therapies: a new horizon
-
2:24
grace targeted therapies lung cancer 2021 - what makes mutations vary?